Quick-Med Technologies, Inc. Signs Joint Development Agreement with a Leading Provider of Health Care Products

Quick-Med Technologies (OTCBB:QMDT) announced today that it has entered into a joint development agreement to develop applications of its NIMBUS® antimicrobial technology with one of the world’s leading providers of health care products. "We are very pleased to be working with this global, high growth health care company,” said J. Ladd Greeno, Chief Executive Officer of Quick-Med Technologies. "This collaboration is an important validation of the unique capabilities of our NIMBUS technology.” The specific terms of the agreement were not disclosed. About Quick-Med Technologies, Inc. Quick-Med Technologies, Inc. (OTCBB:QMDT) is a life sciences company that is developing broad-based technologies for the healthcare and consumer markets. The Company's two core product groups under development are (1) NIMBUS®, a technology employing advanced polymers that can be used in a wide range of applications from advanced wound care to industrial and consumer products; and (2) MultiStat™ family of advanced patented methods and compounds, shown to be effective in key skin care therapy applications for cosmetic, military, and medical markets. For more information, see: www.quickmedtech.com. © 2008 Quick-Med Technologies, Inc. All rights reserved. NIMBUS® and MultiStat™ are trademarks of Quick-Med Technologies, Inc. All other trademarks are the property of their respective owners. Safe Harbor Forward-Looking Statements Certain statements contained in this press release may be deemed to be forward-looking statements under federal securities laws, and Quick-Med Technologies, Inc. intends that such forward looking statements be subject to the safe harbor created thereby. Quick-Med Technologies, Inc. does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.